Anuvat RoongpisuthipongIssaracha SuphanitApisak LuamprapatSumrit SenapadMahidol University2018-07-042018-07-041998-03-01Asian Pacific Journal of Allergy and Immunology. Vol.16, No.1 (1998), 43-470125877X2-s2.0-0031595351https://repository.li.mahidol.ac.th/handle/20.500.14594/18393We have conducted an open, controlled study on the febrile neutropenia effects by Lenograstim (Granocyte®) therapy following cytotoxic chemotherapy of cisplatinum and cyclophosphamide in patients with primary advanced epithelial ovarian cancer. Eligible patients (n = 17) were divided into 2 groups receiving a combined chemotherapy of intravenous cisplatinum (70 mg/m2) and cyclophosphamide (700 mg/m2) with or without the addition of Lenograstim. Subcutaneous administration of Lenograstim (100 μg/day) for 7 consecutive days was given from day 8 to day 14 of the 3(rd) to the 5(th) cycle of chemotherapy in Lenograstim treated patients. After 3 cycles of treatment, Lenograstim treated patients (group 1, n = 10) showed a significant improvement in white blood cell (WBC) count as compared with group 2 (control) of 7 patients (p = 0.00002). Group 1 patients also showed an increased C-reactive protein, though of no significance. There were no significant differences among the 2 groups regarding ESR, hematocrit, platelet counts and blood chemistry profiles. This preliminary data encourages more study of the benefits of Lenograstim in the treatment of ovarian cancer.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS